Blinatumomab como puente al transplante en leucemia linfoblástica aguda refractaria con cromosoma Filadelfia negativoa propósito de un caso

  1. Rodríguez-Ferreras, A. 1
  2. Zapico-García, I. 1
  1. 1 Unidad de Gestión Clínica de Farmacia. Hospital Universitario Central de Asturias
Revista:
Anales del sistema sanitario de Navarra

ISSN: 1137-6627

Ano de publicación: 2019

Volume: 42

Número: 1

Páxinas: 75-78

Tipo: Artigo

DOI: 10.23938/ASSN.0392 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Anales del sistema sanitario de Navarra

Resumo

Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT).We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results. 

Referencias bibliográficas

  • WOLACH O, STONE RM. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor b-cell acute lymphoblastic leukemia. Clin Cancer Res 2015; 21: 4262-4269.
  • TOPP MS, GÖKBUGET N, ZUGMAIER G, KLAPPERS P, STELLJES M, NEUMANN S et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-4140.
  • BENJAMIN JE, STEIN AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol 2016; 7: 142-156.
  • PORTELL CA, WENZELL CM, ADVANI AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acutelymphoblastic leukemia. Clin Pharmacol 2013; 12; 5: 5-11.
  • European Medicines Agency. Ficha técnica de Blinatumomab (Blincyto®). https://ec.europa.eu/health/documents/community-register/2015/20151123133349/anx_133349_es.pdf. Consultado el 2 de octubre de 2018.
  • GÖKBUGET N, DOMBRET H, BONIFACIO M, REICHLE A, GRAUX C, FAUL C et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; 22.
  • ZENG Y1, KATSANIS E. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. Bone Marrow Transplant 2017; 52: 1671-1673.
  • Sociedad Española de Hematología y Hemoterapia. Grupo Programa Español para el Tratamiento de las Hemopatías Malignas. Protocolo LAL-AR/2011 (versión 5 de julio de 2013) para el tratamiento de la leucemia aguda linfoblástica de alto riesgo bcr/abl negativa en adultos. https://www.sehh.es/images/stories/recursos/pethema/protocolos/LAL/LAL_AR_2011version-5-7-2013.pdf.
  • ZUGMAIER G, GÖKBUGET N, KLINGER M, VIARDOT A, STELLJES M, NEUMANN S et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 2015; 126: 2578-2584.
  • FOLAN SA, REXWINKLE A, AUTRY J, BRYAN JC. Blinatumomab: bridging the gap in adult relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2016; 16: S2-5.
  • MARTINELLI G, BOISSEL N, CHEVALLIER P, OTTMANN O, GÖKBUGET N, TOPP MS et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017; 35: 1795-1802.
Fonte de datos: Dialnet